These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2526127)

  • 1. Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin.
    de Vries C; Veerman H; Pannekoek H
    J Biol Chem; 1989 Jul; 264(21):12604-10. PubMed ID: 2526127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous protein.
    Langer-Safer PR; Ahern TJ; Angus LB; Barone KM; Brenner MJ; Horgan PG; Morris GE; Stoudemire JB; Timony GA; Larsen GR
    J Biol Chem; 1991 Feb; 266(6):3715-23. PubMed ID: 1847387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator.
    Silva MM; Thelwell C; Williams SC; Longstaff C
    J Thromb Haemost; 2012 Nov; 10(11):2354-60. PubMed ID: 22974122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
    Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
    J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid.
    van Zonneveld AJ; Veerman H; Pannekoek H
    J Biol Chem; 1986 Oct; 261(30):14214-8. PubMed ID: 3021732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue-type plasminogen activator.
    Fischer BE; Will H
    Biochim Biophys Acta; 1990 Oct; 1041(1):48-54. PubMed ID: 2145980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis.
    Weening-Verhoeff EJ; Quax PH; van Leeuwen RT; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1990 Dec; 4(2):191-8. PubMed ID: 1963688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
    de Vries C; Veerman H; Nesheim ME; Pannekoek H
    Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
    Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
    J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator.
    Beckmann R; Geiger M; de Vries C; Pannekoek H; Binder BR
    J Biol Chem; 1991 Feb; 266(4):2227-32. PubMed ID: 1824940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin.
    Higgins DL; Vehar GA
    Biochemistry; 1987 Dec; 26(24):7786-91. PubMed ID: 2962641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
    Verheijen JH; Caspers MP; Chang GT; de Munk GA; Pouwels PH; Enger-Valk BE
    EMBO J; 1986 Dec; 5(13):3525-30. PubMed ID: 3030730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
    Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
    Lijnen HR; Piérard L; Reff ME; Gheysen D
    Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.
    Suenson E; Bjerrum P; Holm A; Lind B; Meldal M; Selmer J; Petersen LC
    J Biol Chem; 1990 Dec; 265(36):22228-37. PubMed ID: 2148318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.